Exact Sciences launches Cancerguard, a $689 blood test for 50+ cancer types

Abbott Laboratories/Cancerguard

Exact Sciences launched Cancerguard, a multi-cancer early detection blood test sold as a lab-developed test for people aged 50 to 84. It reported 64% sensitivity across cancers other than breast and prostate and 97.4% specificity, with blood drawn at about 7,000 Quest Diagnostics sites.

• Self-pay price $689, eligible for health savings and flexible spending accounts.
• 68% sensitivity across six of the deadliest cancers; 97.4% specificity.
• Positive results lead to an imaging-guided path to diagnosis.
• Falcon registry of up to 25,000 people runs under an FDA investigational exemption.